Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

3.4%

2 terminated/withdrawn out of 58 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

22%

13 trials in Phase 3/4

Results Transparency

13%

2 of 16 completed trials have results

Key Signals

6 recruiting2 with results

Enrollment Performance

Analytics

N/A

11(33.3%)

Phase 4

10(30.3%)

Phase 1

5(15.2%)

Phase 2

4(12.1%)

Phase 3

3(9.1%)

33Total

N/A(11)

Phase 4(10)

Phase 1(5)

Phase 2(4)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (58)

Showing 20 of 58 trials

NCT07265544Recruiting

Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

Role: collaborator

NCT07526363Not Yet Recruiting

Real-world Cohort Study of Antiretroviral Therapy in HIV Patients With Opportunistic Infections

Role: collaborator

NCT05042245Phase 4Completed

The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules

Role: collaborator

NCT07422701Not Yet Recruiting

Portal Vein Thrombosis in Cirrhosis: Incidence, Outcomes and Anticoagulation

Role: collaborator

NCT04896255Recruiting

Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B

Role: collaborator

NCT07170345Recruiting

Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

Role: collaborator

NCT05939167Phase 1Recruiting

Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage

Role: collaborator

NCT06995846Enrolling By Invitation

Application of Bacterial DNA Quantitative Detection in Diagnosis of SBP in Cirrhosis: A Multi Center Diagnostic Experiment

Role: lead

NCT06992479Not ApplicableCompleted

Efficacy of HFNC Combined With Sequential NIV in Patients With COPD Complicated With Type II Respiratory Failure

Role: lead

NCT06773221Not ApplicableNot Yet Recruiting

The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis

Role: collaborator

NCT04011033Phase 2Completed

Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC

Role: lead

NCT03175679Phase 1Completed

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

Role: lead

NCT06280001Not Yet Recruiting

A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of HIV/AIDS Complicated With Infection

Role: collaborator

NCT06272071Not Yet Recruiting

A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of Severe Hepatitis (Liver Failure) Complicated With Infection

Role: collaborator

NCT06279884Not Yet Recruiting

A Cohort Study on the Pathogen Spectrum of Liver Transplant Recipients Complicated With Infection

Role: collaborator

NCT06279845Not Yet Recruiting

A Clinical Cohort Study on the Pathogen Spectrum of Hepatic Virus-caused Cirrhosis Complicated With Infection

Role: collaborator

NCT05962450Phase 2Unknown

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Role: lead

NCT06122753Not ApplicableNot Yet Recruiting

Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis

Role: collaborator

NCT06122792Not ApplicableNot Yet Recruiting

Preemptive TIPS for Gastric Variceal Bleeding in Patients With Cirrhosis

Role: collaborator

NCT05129904Unknown

Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)

Role: collaborator